Glenn Jay Jaffe

I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same implant to treat diabetic macular edema. Recently, I have investigated the use of ultrasonography and optical coherence tomography to diagnose macular edema in a variety of ocular diseases. I have maintained an ongoing basic research program to test the hypothesis that cytokines are important in the development of proliferative vitreoretinopathy, an important intraocular wound healing disorder. Education: I am actively involved in resident and fellow education. I give lectures to residents and fellows on a variety of topics related to uveitis and vitreoretinal diseases and train fellows to perform vitreoretinal surgery. I train post-doctoral students and medical students to conduct clinically relevant research. I serve as a mentor for the Duke third year medical school research program. I have served on a yearly basis as course faculty at many national and international meetings.

Current Appointments & Affiliations

Robert Machemer M.D. Distinguished Professor of Ophthalmology · 2013 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

Professor of Ophthalmology · 1998 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

Chief, Division of Retinal Ophthalmology · 2008 - Present Ophthalmology, Vitreoretinal Diseases & Surgery, Ophthalmology

In the News

Published September 8, 2016

Humira Provides Effective, Non-Steroid Alternative for Eye Inflammation

View All News

Recent Publications

Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.

Journal Article Ophthalmology · April 2026 PURPOSE: Avacincaptad pegol (ACP) is a pegylated RNA aptamer that inhibits complement C5. The efficacy and safety of ACP 2 mg was investigated in GATHER2, with positive year 1 results published. Herein, 2-year results are reported. DESIGN: Phase 3, randomi ... Full text Link to item Cite

Standardization of Imaging Criteria for Detecting Macular Fibrosis in Neovascular Age-Related Macular Degeneration.

Journal Article Ophthalmol Sci · February 2026 PURPOSE: To evaluate conventional imaging modalities for detecting fibrosis in neovascular age-related macular degeneration (nAMD) and to develop a standardized diagnostic workflow. DESIGN: Systematic discussion and grading exercise assessing multiple imag ... Full text Link to item Cite

Standardizing Measurement of Complete Retinal Pigment Epithelial and Outer Retinal Atrophy-Classification of Atrophy Meeting Report 8.

Journal Article Ophthalmol Retina · January 30, 2026 PURPOSE: To highlight the role of en face OCT in the measurement of choroidal hypertransmission defects (hyperTDs) in complete retinal pigment epithelial and outer retinal atrophy (cRORA), and to refine the definition of retinal pigment epithelium (RPE)-re ... Full text Link to item Cite

View All Publications

Recent Grants

A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (AQUARIUS)

ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2026 - 2032

A Ph 4, Multicenter, Open-label Study to Evaluate Long-term Safety and Efficacy of Revakinagene Taroretcel-Lwey (NT-501) Previously Implanted in a Ph 1, Ph 2, or Ph 3 Clinical Study and to Evaluate NT-501 Implanted in Participants...

ResearchPrincipal Investigator · Awarded by Neurotech Pharmaceuticals, Inc. · 2025 - 2030

A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)

ResearchPrincipal Investigator · Awarded by Adverum Biotechnologies, Inc · 2022 - 2029

View All Grants

Education

University of California San Francisco, School of Medicine · 1983 M.D.